Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Proteins|November 23, 2006
Genome-based identification and characterization of a putative mucin-binding protein from the surface of Streptococcus pneumoniaeDaniela Bumbaca, James E Littlejohn, Hannah Nayakanti, et al.
Toxicologic Pathology|November 18, 2020
Nonclinical Toxicology and Biocompatibility Program Supporting Clinical Development and Registration of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular DegenerationVladimir Bantseev, Joshua Horvath, Giulio Barteselli, et al.
Frontiers in Pharmacology|September 19, 2022
PBPK-PD modeling for the preclinical development and clinical translation of tau antibodies for Alzheimer's diseasePeter Bloomingdale, Daniela Bumbaca-Yadav, Jonathan Sugam, et al.
Journal of Pharmacokinetics and Pharmacodynamics|August 11, 2021
Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseasesPeter Bloomingdale, Suruchi Bakshi, Christian Maass, et al.
Molecular Pharmaceutics|February 7, 2013
Vascular physiology and protein disposition in a preclinical model of neurodegenerationC Andrew Boswell, Eduardo E Mundo, Bernadette Johnstone, et al.
Molecular Cancer Therapeutics|April 27, 2018
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer CellsGuangmin Li, Jun Guo, Ben-Quan Shen, et al.
Plos One|March 26, 2011
Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flowC Andrew Boswell, Gregory Z Ferl, Eduardo E Mundo, et al.
Mabs|May 5, 2011
Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4Daniela Bumbaca, Anne Wong, Elizabeth Drake, et al.
Current Drug Metabolism|April 6, 2012
Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolismBen-Quan Shen, Daniela Bumbaca, Ola Saad, et al.
Mabs|February 27, 2016
Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitorRong Deng, Daniela Bumbaca, Cinthia V Pastuskovas, et al.
Pageof 5